Organogenesis Holdings (ORGO) Net Income towards Common Stockholders Growth (1y) (2017 - 2026)
Organogenesis Holdings (ORGO) Net Income towards Common Stockholders Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -304.98% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -17.29% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 7.59% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -2,482.61% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 34.33% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 390.91% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Organogenesis Holdings | 238.69 Mn | 191.85 Mn | 20.08 Mn | -714.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -714.12% |
| Mar 31, 2026 | -160.10% |
| Dec 31, 2025 | 593.82% |
| Sep 30, 2025 | 17.79% |
| Jun 30, 2025 | 28.40% |
| Mar 31, 2025 | -928.14% |
| Dec 31, 2024 | 306.86% |
| Sep 30, 2024 | 289.36% |
| Jun 30, 2024 | -420.60% |
| Mar 31, 2024 | 29.27% |
| Dec 31, 2023 | -80.71% |
| Sep 30, 2023 | 1,373.02% |
| Jun 30, 2023 | -39.20% |
| Mar 31, 2023 | -225.19% |
| Dec 31, 2022 | -60.64% |
| Sep 30, 2022 | -98.29% |
| Jun 30, 2022 | -57.73% |
| Mar 31, 2022 | -109.18% |
| Dec 31, 2021 | 6.97% |
| Sep 30, 2021 | -39.92% |